PMID- 34795583
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220317
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - TNF-alpha in Uveitis: From Bench to Clinic.
PG  - 740057
LID - 10.3389/fphar.2021.740057 [doi]
LID - 740057
AB  - Uveitis is an inflammation of the iris, ciliary body, vitreous, retina, or 
      choroid, which has been shown to be the first manifestation of numerous systemic 
      diseases. Studies about the immunopathogenesis and treatment of uveitis are 
      helpful to comprehend systemic autoimmune diseases, and delay the progression of 
      systemic autoimmune diseases, respectively. Tumor necrosis factor-alpha (TNF-alpha), 
      a pleiotropic cytokine, plays a pivotal role in intraocular inflammation based on 
      experimental and clinical data. Evidence of the feasibility of using anti-TNF-alpha 
      agents for uveitis management has increased. Although there are numerous studies 
      on TNF-alpha in various autoimmune diseases, the pathological mechanism and research 
      progress of TNF-alpha in uveitis have not been reviewed. Therefore, the objective of 
      this review is to provide a background on the role of TNF-alpha in the 
      immunopathogenesis of uveitis, as well as from bench to clinical research 
      progress, to better guide TNF-alpha-based therapeutics for uveitis.
CI  - Copyright (c) 2021 Jiang, Li, Tao, Duan, Wang and Su.
FAU - Jiang, Qi
AU  - Jiang Q
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Li, Zhaohuai
AU  - Li Z
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Tao, Tianyu
AU  - Tao T
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Duan, Runping
AU  - Duan R
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Wang, Xianggui
AU  - Wang X
AD  - Eye Center of Xiangya Hospital, Central South University, Changsha, China.
AD  - Hunan Key Laboratory of Ophthalmology, Changsha, China.
FAU - Su, Wenru
AU  - Su W
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211102
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
EIN - Front Pharmacol. 2022 Feb 25;13:817235. PMID: 35281920
PMC - PMC8592912
OTO - NOTNLM
OT  - TNF-alpha
OT  - adalimumab
OT  - anti-TNF-alpha agents
OT  - certolizumab pegol
OT  - experimental autoimmune uveitis (EAU)
OT  - golimumab
OT  - infliximab
OT  - uveitis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. The handling editor is currently organizing a Research 
      Topic with one of the authors WS.
EDAT- 2021/11/20 06:00
MHDA- 2021/11/20 06:01
PMCR- 2021/11/02
CRDT- 2021/11/19 06:53
PHST- 2021/07/12 00:00 [received]
PHST- 2021/10/19 00:00 [accepted]
PHST- 2021/11/19 06:53 [entrez]
PHST- 2021/11/20 06:00 [pubmed]
PHST- 2021/11/20 06:01 [medline]
PHST- 2021/11/02 00:00 [pmc-release]
AID - 740057 [pii]
AID - 10.3389/fphar.2021.740057 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Nov 2;12:740057. doi: 10.3389/fphar.2021.740057. 
      eCollection 2021.